Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

102.99 -0.99 (-0.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 605,028
Open 103.89
Bid (Size) 102.27 (1)
Ask (Size) 103.49 (1)
Prev. Close 103.98
Today's Range 102.51 - 104.41
52wk Range 64.11 - 139.13
Shares Outstanding 47,190,970
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Why Is Teva Stock Trading Higher On Tuesday?
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design. 
Via Benzinga

Performance

YTD
+17.9%
+17.9%
1 Month
-4.0%
-4.0%
3 Month
-21.2%
-21.2%
6 Month
+5.6%
+5.6%
1 Year
+34.2%
+34.2%

More News

Read More
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For May 5, 2025
Via Benzinga
3 High-Flying Stocks That Could Soar Even More
Via The Motley Fool
Exposures Product Safety
Expert Outlook: Axsome Therapeutics Through The Eyes Of 16 Analysts
Via Benzinga
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis
Via The Motley Fool
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years
Via The Motley Fool
3 Monster Stocks in the Making
Via The Motley Fool
Axsome Therapeutics Clocks Around 60% Topline Growth In Q1
Via Benzinga
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings)
Via Benzinga
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO DISMISS: Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); and Virtu Financial Inc. (NASDAQ: VIRT)
From Grabar Law Office
Via GlobeNewswire
Attention Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra Lifesciences Holdings Corporation (NASDAQ: IART); and Virtu Financial Inc. (NASDAQ: VIRT): Grabar Law Office Investigates
From Grabar Law Office
Via GlobeNewswire
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions
From Grabar Law Office
Via GlobeNewswire
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
From Axsome Therapeutics, Inc.
Via GlobeNewswire
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions
From Grabar Law Office
Via GlobeNewswire
SECURITIES FRAUD CLASS ACTIONS SURVIVE MOTIONS TO DISMISS: Grabar Law Office Investigates Claims on Behalf of Shareholders of Arqit Quantum Inc. (NASDAQ: ARQQ); Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); and Maison Solutions
From Grabar Law Office
Via GlobeNewswire
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Stocks Edge Higher Despite Trade, Economic Jitters
Via Talk Markets
Topics Stocks / Equities
Why Shares of Axsome Therapeutics Slumped Today
Via The Motley Fool

Frequently Asked Questions

Is Axsome Therapeutics, Inc. - Common Stock publicly traded?
Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?
Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?
The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market
What is the current price of Axsome Therapeutics, Inc. - Common Stock?
The current price of Axsome Therapeutics, Inc. - Common Stock is 102.99
When was Axsome Therapeutics, Inc. - Common Stock last traded?
The last trade of Axsome Therapeutics, Inc. - Common Stock was at 05/28/25 04:00 PM ET
What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?
The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 4.86B
How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?
Axsome Therapeutics, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.